Ardent Health Shares Dive 33% After Q3 Surge Meets Margin Headwinds

Ardent Health (ARDT) shares plunged 33.02% to $9.41 after the company reported its third-quarter 2025 results and significantly lowered its full-year adjusted EBITDA guidance. Despite an 8.8% year-over-year revenue increase to $1.58 billion and a 46.3% rise in adjusted EBITDA to $143 million, the firm cut its full-year outlook to $530-$555 million from $575-$615 million, citing accelerating professional fee expense growth and increased payor denials, leading to heavy trading volume.

Analysis

Ardent Health (ARDT) shares plummeted 33.02% to $9.41 following its Q3 2025 earnings report, driven primarily by a significant reduction in full-year adjusted EBITDA guidance. This sharp decline, accompanied by unusually heavy trading volume, indicates a strong negative market reaction to the revised outlook. The stock is now trading near its 52-week low of $9.00.

Despite the negative market response, the company reported robust Q3 2025 operational results, with revenue increasing 8.8% year-over-year to $1.58 billion and adjusted EBITDA surging 46.3% to $143 million. However, this strong quarterly performance was overshadowed by the cut to full-year adjusted EBITDA guidance from $575-$615 million to $530-$555 million.

The guidance reduction was attributed to accelerating professional fee expense growth and an uptick in payor denials, highlighting increasing operational pressures within the healthcare sector. These factors suggest potential margin compression and uncertainty regarding future profitability, eroding investor confidence despite current top-line growth.

Key Decisions for Investors

• Closely monitor Ardent Health's ability to mitigate accelerating professional fee expenses and address the uptick in payor denials, as these operational headwinds directly impact future profitability
• Re-evaluate ARDT's valuation multiples against its revised, lower full-year adjusted EBITDA guidance to assess potential further downside risk
• Consider holding off on new long positions until there is clear evidence of stabilization in operational costs and payor relations